Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Relay Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08 | Direct | 32,947 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 10, 2026 20:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 32,947 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-265904 · ownership.xml · derivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,947 Underlying: Common Stock · 32,947 shares Expires 2036-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 21:51 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 136,681 | $0.00 Strike: $3.36 | $0.00 |
DisclosureSEC source: 0000950170-25-083306 · ownership.xml · derivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,681 Underlying: Common Stock · 136,681 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| June 03, 2024 Filed Jun 6, 2024 00:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 102,225 | $0.00 Strike: $6.79 | $0.00 |
DisclosureSEC source: 0000950170-24-069560 · ownership.xml · derivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,225 Underlying: Common Stock · 102,225 shares Expires 2034-06-02 F1 · derivative.exercise_date: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 22:37 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 66,055 | $0.00 Strike: $11.14 | $0.00 |
DisclosureSEC source: 0001209191-23-033436 · doc4.xml · derivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,055 Underlying: Common Stock · 66,055 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| September 08, 2022 Filed Sep 9, 2022 00:31 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 25,000 | $29.95 | $748,750.00 |
DisclosureSEC source: 0001209191-22-049246 · doc4.xml · nonDerivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,952 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2022. Read SEC document |
| May 27, 2022 Filed May 27, 2022 21:41 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 41,597 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001209191-22-032685 · doc4.xml · derivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Common Stock · 41,597 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| May 19, 2021 Filed May 21, 2021 23:44 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001209191-21-035114 · doc4.xml · derivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionSeries B Convertible Preferred Stock · Derivative | 990,099 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019846 · doc4.xml · derivative · entry 5 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 278,829 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. F2 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019846 · doc4.xml · derivative · entry 4 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 281,617 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. F2 · derivative.exercise_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | PurchaseCommon Stock | 25,000 | $20.00 | $500,000.00 |
DisclosureSEC source: 0000899243-20-019846 · doc4.xml · nonDerivative · entry 3 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,021,952 F3 · price: On July 20, 2020, the reporting person purchased 25,000 shares of Common Stock of the Issuer at a price of $20.00 per share pursuant to an underwritten public offering. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionCommon Stock | 278,829 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019846 · doc4.xml · nonDerivative · entry 2 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 996,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. Read SEC document |
| July 20, 2020 Filed Jul 21, 2020 23:19 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | ConversionCommon Stock | 281,617 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019846 · doc4.xml · nonDerivative · entry 1 Murcko Mark · CIK 0001816130 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.